A randomized, double-blind, parallel-group, multicenter study to compare the glycemic effects, safety, and tolerability of exenatide long-acting release (once weekly) to those of sitagliptin and a thiazolidinedione in subjects with type 2 diabetes mellitus treated with metformin.

Trial Profile

A randomized, double-blind, parallel-group, multicenter study to compare the glycemic effects, safety, and tolerability of exenatide long-acting release (once weekly) to those of sitagliptin and a thiazolidinedione in subjects with type 2 diabetes mellitus treated with metformin.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2018

At a glance

  • Drugs Exenatide (Primary) ; Pioglitazone; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DURATION-2
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 01 Apr 2018 Results of pooled post hoc analysis of this and other ten trials assessing the relationship of heart rate changes with baseline heart rate and identifying patient characteristics associated with changes in heart rate in the Exenatide QW development program published in the Diabetes Therapy
    • 10 Jun 2017 Biomarkers information updated
    • 28 Jun 2011 Pooled efficacy analysis results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top